Literature DB >> 22244722

Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura.

Pier Mannuccio Mannucci1, Massimo Franchini.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare but severe disease characterized by mechanical hemolytic anemia and consumptive thrombocytopenia leading to disseminated microvascular thrombosis that causes signs and symptoms of organ ischemia and functional damage. After the elucidation of the pathophysiology of TTP, thanks to the demonstration of the congenital or acquired (autoimmune) plasma deficiency of the von Willebrand factor cleaving metalloprotease A Disintegrin And Metalloprotease with ThromboSpondin 1 repeats (ADAMTS13), a number of laboratory assays for measuring ADAMTS13 and related autoantibodies have been developed. Current knowledge on the diagnostic and prognostic value of ADAMTS13 and anti-ADAMTS13 assays is summarized in this review. Copyright Â
© 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244722     DOI: 10.1016/j.lpm.2011.10.025

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

Review 1.  Thrombotic microangiopathy and associated renal disorders.

Authors:  Thomas Barbour; Sally Johnson; Solomon Cohney; Peter Hughes
Journal:  Nephrol Dial Transplant       Date:  2012-07       Impact factor: 5.992

2.  Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals.

Authors:  Angela Liu; Noor Dhaliwal; Harshvardhan Upreti; Jamil Kasmani; Kathryn Dane; Alison Moliterno; Evan Braunstein; Robert Brodsky; Shruti Chaturvedi
Journal:  Transfusion       Date:  2020-11-12       Impact factor: 3.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.